TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$115 Million

Alpine Immune Sciences, Inc.

Follow-on Offering

Bookrunner, September 2022

Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. (ALPN) (“Alpine Immune Sciences” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Alpine Immune Sciences’ approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. The Company believes its strategies are capable of meaningfully modulating the human immune system and significantly improving outcomes in patients with serious diseases.